MGMT methylation analysis was performed in 95 samples, and methylated profile was found in 31 cases (32.6%). GCB was found in 6 cases (22.2%) and non-GCB was determined in 25 cases (36.8%) out of 31 with MGMT methylated samples. There was no significant association between MGMT methylation status and immunophenotypic profiles (p=0.173).
Introduction
Diffuse large B-cell lymphoma (DLBCL) constitutes the largest group of aggressive lymphomas in adults and 30-40% of adult non-Hodgkin lymphomas (NHL) in western countries [1, 2] . DLBCLs show diversity in clinical presentation, morphology and genetic and molecular properties, which suggests that these tumors represent a heterogeneous group of neoplasms rather than a single clinicopathologic entity [2, 3] . Therefore, patients who are diagnosed as DLBCL could show remarkably different history, clinical behavior and outcome [1] .
Different mechanisms such as deregulation of cell cycle and apoptotic pathways are involved in the pathogenesis of DLBCL. As for the molecular pathogenesis of DLBCL, distinct chromosomal translocations and aberrant somatic hypermutations as well as numerical chromosomal anomalies such as duplications and deletions, which are also common to other malignancies, have been reported [4] [5] [6] [7] . DLBCL originates from germinal center (GC) and post-GC B-cells that normally have encountered with antigen [8, 9] . Different methods are applied to determine B-cell differentiation antigens in DLBCL. In spite of the distinct advantages of cDNA and oligonucleotide microarray techniques, immunohistochemistry is a commonly used method to determine the GC B-cell-like (GCB) and non-GCB-like profiles because it is cheap and easily applied [10] [11] [12] . Hans et al. [11] reported that the classification of DLBCL into GCB and non-GCB profiles based on CD10/ bcl-6/MUM1 immunophenotypic differentiation is prognostically relevant to the cDNA classification in 71% of GCB and in 88% of non-GCB. It is well known that the expression of bcl-6 and CD10 are associated with increased apoptosis and proliferation in lymphoid malignancies [13] [14] [15] [16] [17] [18] . Bai et al. [10] reported that increased expression of apoptotic index (AI) in DLBCL with GCB profile is associated with high expression of the pro-apoptotic proteins (bax, bak, bid) and low expression of the antiapoptotic protein (bcl-xl). However, data related to apop- Sonuç: Bu bulgular, bcl-6 protein ekspresyonunun GCB'de yüksek PI'inden sorumlu olabileceğini öne sürmektedir. Ek olarak, apoptozis-ilişkili proteinlerin immünofenotipik profilerle anlamlı ilişki göstermediğini saptadık. (Turk J Hematol 2011; 28: 15-26) Anahtar kelimeler: Büyük B-hücreli lenfomalarda apoptosis ve proliferasyon tosis and proliferation status in CD10/bcl-6/MUM1 immunophenotypic differentiation profiles is considerably limited. Although the immunohistochemical expression of the apoptosis-associated bcl-2 family proteins, bcl-2, bax, bak, and mcl1, was reported in DLBCLs [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] , the expression levels of bcl-xl, bad, bid proteins and their relations with the status of apoptosis and proliferation were not extensively analyzed in these lymphomas [25] .
Altered DNA methylation profile has been comprehensively studied in the pathogenesis of cancer. Compared with normal cells, cancer cells frequently demonstrate genome-wide hypomethylation, hypermethylation of tumor suppressor gene, and loss of genomic imprinting [29] . In human cancers, the gene encoding the DNA-repair enzyme O 6 -methylguanine-DNA methyltransferase (MGMT) is not commonly mutated or deleted. Loss of MGMT expression is mainly due to epigenetic changes, specifically methylation of the promoter region [1, 30] . MGMT protects cells from the toxicity of environmental and therapeutic alkylating agents, which frequently target the O 6 position of guanine. Inactivation of the MGMT gene via hypermethylation of its promoter region increases sensitivity of cells to the genotoxic effect of alkylating agents both in vitro and in vivo [1, 3] . Recent research has focused on the relationship between MGMTmethylation status and immunophenotypic differentiation in DLBCLs [30, 31] .
The aim of this study was to investigate the expression profiles of apoptosis-associated proteins (bcl-2, bcl-xl, bax, bak, bid), apoptotic index (AI), and proliferation index (PI) in GCB and non-GCB immunophenotypic profiles of DLBCL. In addition, the methylation status of the promoter region of the MGMT gene and its relation with immunophenotypic differentiation of DLBCLs were investigated.
Materials and Methods

Materials
A total of 101 cases of de novo DLBCLs, diagnosed according to the World Health Organization (WHO) classification [2] , were obtained from the files of the Department of Pathology, Faculty of Medicine, Ege University. Clinicopathological parameters for all patients were obtained from the pathology records. Ethical committee approval was obtained for this study.
Immunohistochemistry
For immunohistochemical staining, sections of 5-μm-thickness were cut from formalin-fixed, paraffin-embedded tissue blocks and placed on electrostatic-charged, poly-L-lysine-coated slides (X-traTM, Surgipath Medical Industries, Richmond, IL, USA). Sections were dehydrated at 60ºC for a minimum of 2 hours (h). All immunostaining procedures including deparaffinization and antigen retrieval processes were performed on BenchMark XT ® automated stainer (Venatana Medical Systems, USA). After counterstaining of the slides with hematoxylin in automated stainer, dehydration, incubation in xylene and mounting processes were performed manually, and immunostaining procedure was completed. Reactive lymph nodes and normal thymic tissue samples were used as positive controls. Negative controls were treated with the same immunohistochemical method by omitting the primary antibody.
At least 10 fields selected on the basis that they contained immunopositive cells were counted by using the 40x objective lens on the light microscope. The number of immunopositive cells was divided by the total number of the counted cells, and the expression was defined as the percentage of positive cells. CD10, bcl-6, and MUM1 proteins were considered positive when at least 25% of neoplastic cells were immunopositive according to the previously defined criteria [12] . The CD10/bcl-6/MUM1 immunophenotypes and their designation to GCB and non-GCB profiles were determined according to the classification by Hans et al. [11] . The expressions of bcl-2, bcl-xl, bax, bak, and bid proteins were considered positive when at least 10% of neoplastic cells were immunopositive [10] . PI with Ki-67 was determined as the percentage of positive cells within the total number of the counted cells.
Tunel Method
The terminal deoxynucleotidyl-transferase (TdT)-mediated in situ labeling technique (TUNEL; in situ Cell Death Detection Kit, POD, Roche) was performed on the 5-μm-thick sections of formalinfixed, paraffin-embedded tissue for demonstration of DNA fragmentation. Briefly, after deparaffinization and dehydration, slides were rinsed in phosphate-buffered saline (PBS) (pH 7.4). The peroxidase activity was blocked by incubation for 15 minutes (min) in 3% hydrogen peroxide in PBS at room temperature. Tissue sections were digested by incubation for 30 min with proteinase K (20 μg/ml) at 37ºC, and then were rinsed in PBS. TUNEL reaction mixture was prepared according to the manufacturer's recommendations, and a mixture of 50 μL per slide was added. Slides were incubated for 1 h at 37ºC in dark. One positive control and two negative controls were included in each set of experiments. Reactive lymph nodes were used as positive controls. Negative controls were treated similarly by omitting the TdT reaction step. Slides, once again, were rinsed in PBS. To examine the slides in light microscope, 50 μl Converter-peroxidase (POD) was added per slide and slides were incubated for 30 min at 37ºC in humid and dark conditions. Slides were rinsed in PBS, and then were incubated with 3,3'-diaminobenzidine tetrahydrochloride (DAB Substrate, Roche) for 10 min at room temperature. Slides were counterstained with Harris' hematoxylin and mounted. The evaluation of the results was performed as Bai et al. [32] had described previously. Morphologically intact TUNEL-positive cells were considered as positive and referred to as apoptotic cells. The number of apoptotic cells was recorded by using the 40X objective in at least 10 randomly selected fields. The AI was expressed as a percentage of the number of apoptotic cells within the total number of counted cells.
O 6 -Methylguanine-DNA Methyltransferase Methylation Analysis
Genomic DNAs were extracted from four or five 5-μm-thick sections of formalin-fixed, paraffinembedded tissue, using a commercial kit (QIAamp DNA Mini Kit, Qiagen, Valencia, CA). Briefly, after deparaffinization with xylene, tissue samples were digested with proteinase K treatment. DNAs that emerged from cells were collected in the column through ethanol treatment. Cellular remnants and chemical agents were removed by washing buffer, and genomic DNA was eluted in DNAase-free buffer and stored at -20ºC.
Commercial kit (EZ Methylation Gold-Kit, Zymo Research, Orange, CA) was used for bisulfite modification of isolated DNA. Briefly, DNA concentration was measured and arranged to make 500 ng/μL, and 130 μL conversion reagent was added to 20 μL DNA sample. Samples were incubated for 10 min at 98ºC and then for 2.5 h at 64ºC. Samples were transferred to column with 600 μL M-binding buffer. After homogenization, samples were centrifuged. Samples were rinsed with 100 μL M-wash buffer, and were then incubated in 200 μL M-desulfonation buffer for 20 min at room temperature. After incubation, samples were rinsed two times, and then 10 μL M-elution buffer was added. Sodium bisulfite-treated genomic DNA was stored at -20ºC.
Primer and probe sequences of the promoter region of MGMT gene were used, which target the localization of 1067 -1149 bp amplicon, as described by Esteller et al. (33) (GenBank Accession Number: X61657). Final reaction volume for analysis of both methylated and unmethylated profiles was performed in 20 μL volume: 2 μl from each primer (final concentration: 0.5 μM), 2 μl TaqMan probe (final concentration: 0.2 μM), 4 μl LightCycler TaqMan Master mixture, 5 μl DNA sample, and 5 μl polymerase chain reaction (PCR)-grade water. The cycling conditions for methylation-specific PCR were: 10 min at 95ºC for Taq activation, followed by 45 cycles of 95ºC for 10 seconds (sec), 60ºC for 20 sec, and 72ºC for 1 sec for amplification. PCR products were run on a 3% agarose gel containing ethidium bromide. (Figure 1 A-E) . The mean PI was 46.15% (±32.82) as assessed by Ki-67 staining. The mean AI was 1.94% (±2.68) as determined by the TUNEL method (Figure 1 F) .
Statistical Analysis
Two major immunophenotypic profiles were distinguished according to the pattern of differentiation described by Hans et al. [11] : (a) GCB immunophenotypic profile: 29 cases (CD10+: 20 cases, CD10-/ bcl-6+ /MUM1-: 9 cases) and (b) non-GCB immunophenotypic profile: 72 cases (CD10-/bcl-6-: 47 cases, CD10-/bcl-6+ /MUM1+: 25 cases) ( Table 1) .
Mann-Whitney test was used to analyze the association of two immunophenotypic differentiation profiles in relation to the AI, the expression levels of apoptosis-related proteins and PI (Ki-67) ( Table 2) . Compared to the non-GCB profile, the GCB profile was significantly associated with a higher PI (p=0.011). However, no other significant correlations were determined between the two major differentiation immunophenotypic profiles regarding AI and the expression levels of apoptosis-related proteins bcl-2, bcl-xl, bax, bak, and bid (p>0.3).
The percentage of cells stained by CD10, bcl-6 and MUM1 were analyzed in relation to apoptosisrelated proteins, AI and PI by Spearman correlation coefficient test, regardless of previous evaluation with cut-off points to consider the results as positive or negative (Table 3 ). The expression of bcl6 was positively correlated with the expression of bcl2 (r=0.226, p=0.023), the AI (r=0.272, p=0.006) and the PI (r=0.515, p<0.001), but a significantly negative correlation was observed with the expression of bax (r=-0.221, p=0.027). The expression of MUM1 showed significant positive correlation with the expression of bcl-xl (r=0.295, p=0.003), bid (r=0.313, p=0.002), AI (r=0.341, p<0.001), and PI MGMT promoter methylation analysis was performed in 95 patients with DLBCL ( Figure 2 ). MGMT methylated profile was found in 31/95 (32.6%) samples while MGMT unmethylated profile was determined in 64/95 (67.4%) samples. The GCB profile was determined in 6 cases (22.2%) and non-GCB profile in 25 cases (36.8%) out of the 31 with MGMT methylated profile (Table 4 ). There was no significant association between MGMT promoter methylation status and the two immunophenotypic differentiation profiles (p=0.173) ( Table 5 ). There was also no significant association between MGMT promoter methylation status and the expression levels of apoptosis-related proteins, the AI and the PI (p>0.06).
Discussion
In the present study, we found that in DLBCLs, the GCB profile was significantly associated with a higher PI compared to the non-GCB profile. In addition, the percentage of cells reacting with the GC B-cell-related bcl-6 protein showed significant positive correlation with PI. The correlation between bcl-6 and proliferation is not conclusive in the published data. A review of the literature indicates that bcl-6 could have a role both as stimulator or inhibitor of cell cycle progression and proliferation [16, [32] [33] [34] [35] [36] [37] . Some in vitro studies showed that bcl-6 expression was associated with delaying cell cycle progression and decreased proliferation [15, 35] . Albagli et al. [16] demonstrated that bcl-6 mediates growth suppression associated with impaired S phase progression in human U2OS osteosarcoma cells. Hosokawa et al. [35] established Ba/F3 pro-B cells carrying a human bcl-6 transgene, and revealed that Turk J Hematol 2011; 28: 15-26 induced bcl-6 protein downregulates the expression of cyclin A2 and inhibits cell proliferation, though Shaffer et al. [34] demonstrated that bcl-6 may induce cell cycle progression and maintain proliferation by blocking the expression of the cyclindependent kinase inhibitor p27 and by repressing blimp-1 expression, which decreases c-myc expression. Furthermore, Allman et al. [37] revealed that bcl-6 protein expression was 34-fold higher in rapidly proliferating GC B-cells than in the resting B-cells. Bai et al. [18] suggested that the resistance to antiproliferative signals through the P19 (ARF) -p53 pathway and downregulation of the expression of cyclin-dependent kinase inhibitor p27 are at least partly responsible for the association between bcl-6 and increased proliferation in DLBCL. Xu et al. [38] investigated the role of bcl-6 gene rearrangement and bcl-6 expression in subgroups of DLBCLs and showed that DLBCLs with bcl-6 gene rearrangement had higher proliferative activity than those without bcl-6 gene rearrangement. On the basis of the previously mentioned results, results of this study suggest that bcl-6 protein expression could be responsible for high PI in the GCB profile of DLBCL.
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Additionally, in this study, bcl-6 expression showed significant positive correlation with the AI and anti-apoptotic protein bcl-2 expression and negative correlation with pro-apoptotic protein bax expression. In association with the proliferation of bcl-6, the data in the literature indicates that bcl-6 may have a role as stimulator or inhibitor of apoptosis [15, 16, [39] [40] [41] . Some studies showed that bcl-6 may protect cells from apoptosis [39, 41] . Kojima et al. [39] demonstrated that bcl-6 may have a stabilizing role to protect spermatocytes from heat shockinduced apoptosis in bcl-6-deficient mice. Baron et al. [41] showed that the human programmed cell death-2 (PDCD2) gene is a target of bcl-6 repression in Epstein-Barr virus-negative Burkitt lymphoma cell line expressing high levels of bcl-6. Furthermore, they immunohistochemically demonstrated the inverse relationship between bcl-6 and PDCD2 expression in human tonsils [41] . Consequently, they proposed that bcl-6 may downregulate apoptosis by means of its repressive effects on PDCD2. However, some other studies suggested that high expression of bcl-6 may induce apoptosis [14] [15] [16] 40] . Albagli et al. [16] used the human osteosarcoma cell line U2OS transfected with bcl-6 and demonstrated that bcl-6 mediates dose-dependent growth suppression, which is associated with impaired S phase progression and trigger of apoptosis. Yamochi et al. [14] showed that viability of CV-1 and HeLa cells infected with a recombinant adenovirus expressing bcl-6 was markedly reduced due to apoptosis. Furthermore, induction of apoptosis by bcl-6 overexpression was preceded by downregulation of apoptosis repressors bcl-2 and bcl-xl, which suggests that bcl-6 might also regulate the expression of these apoptosis repressors [14] . Bai et al. [18] found that high expression of bcl-6 shows significant correlation with negative bcl-2 expression. They suggested that the association between increased bcl-6 expression and increased apoptosis in DLBCL might be due, at least to some extent, to the downregulation of bcl-2, which is induced by bcl-6 overexpression [18] . In contrast to previous studies, in this study, we determined that bcl-6 expression shows a significantly positive correlation with bcl-2 expression. Moreover, we found that bcl-6 expression shows significant negative correlation with pro-apoptotic protein bax expression. It is well known that apoptosis-related proteins bcl-2 and bclxl show anti-apoptotic effect, whereas bax, bak and bid show pro-apoptotic function. These proteins, as members of the bcl-2 family, exert their specific effects by dimerizing with themselves or with each other [25] . If the balance favors the presence of free bcl-2, apoptosis is inhibited, whereas when bax predominates, apoptosis is initiated [25] . Thus, the ratio of the anti-apoptotic to the pro-apoptotic proteins determines whether a given cell will respond to or ignore an apoptotic stimulus [25] . On the basis of these results, we suggest that pro-apoptotic function of bcl-6 partly occurs independent of an anti-apoptotic effect of bcl-2 and pro-apoptotic effect of bax. In this study, no significant correlations were determined between two major immunophenotypic differentiation profiles regarding AI and the expression levels of apoptosis-related proteins bcl-2, bcl-xl, bax, bak, and bid. However the percentage of cells positive for MUM1, which is major marker of non-GCB immunophenotypic differentiation profile, showed a significantly positive correlation with the positivity percentage of anti-apoptotic protein bcl-xl, pro-apoptotic protein bid, AI, and PI. Bai et al. [10] determined that the expression of MUM1 showed significant negative correlation with the expression of bax and bid and significant positive correlation with the expression of bcl-xl. They proposed that this result may provide an explanation for the significant positive correlation between MUM1 and bcl-xl expression in their study, because the MUM1 (IRF4) gene is also a nuclear factor-Kappa B target. Nuclear factorKappa B, depending on the stimulus and the cellular context, can activate pro-apoptotic (e.g. CD95, CD95L, TRAIL receptors), anti-apoptotic (c-FLIP, bcl-2, bcl-xl, c-IAP1, c-IAP2) and cell cycle (cyclin D1, cyclin D2, c-myc) genes [32] . This status may explain how MUM1 expression shows significant positive correlation with pro-apoptotic protein bid, AI, PI, as was also shown in the results of Bai et al. [10] .
In this study, we determined that DLBCLs frequently express bcl-2 family member apoptosisrelated proteins as bcl-2 in 31.7%, bcl-xl in 7.9%, bax in 66.3%, bak in 81.2%, and bid in 66.3%. Bairey et al. [25] examined the role of bcl-2 family proteins in aggressive NHLs and determined that of the entire group of 44 samples, 25 (57%) showed bcl-2 staining, 11 (25%) showed bcl-xl staining, 17 (39%) showed bax staining, and 16 (36%) showed bak staining. Among these proteins, bcl-2, the most exclusively investigated, is a potent suppressor of apoptosis and is determined in unexpectedly high levels probably in all cancers of humans [50] . Simonian et al. [43] suggested that bcl-2 and bcl-xl can downregulate or upregulate apoptosis. Sclaifer et al. [44] showed that all cases with a positive expression of bax expressed either bcl-2 or mcl-1 anti-apoptotic proteins, suggesting that the presence of bax in the tumor cells must be associated with apoptosis-inhibiting proteins, allowing malignant cell survival. Kiberu et al. [22] investigated the correlation between apoptosis, proliferation and bcl-2 expression in NHLs, and they suggested that expression of bcl-2 is not necessarily related to low levels of apoptosis, as some bcl-2 positive highgrade tumors also had high levels of apoptosis. Nevertheless, they found that the majority of lymphomas expressing bcl-2 had average levels of apoptosis [22] . These results suggested that bcl-2 independent apoptosis is an important factor influencing cell death in many NHLs [22] . Overall results of previous studies [10, 19, [22] [23] [24] [25] [26] [27] and our results indicate that the expressions of bcl-2 family proteins are variable and heterogeneous in DLBCL. The dual effect of bcl-2 family proteins may show individual variation in the pathogenesis and prognosis of DLBCLs.
In this study, we found that the AI showed significant positive correlation with the PI. This result is correlated with previously reported results [10, 22, 45] . However, we were unable to show any relation between apoptosis-related proteins and PI.
In this study, we determined that MGMT promoter methylation was detected in 32.6% of cases. MGMT methylation was reported at a frequency from 36% to 52% in Western populations in previous studies [1, 3, 30, 46, 47] . Higher rates (75.9%) were found in Middle Eastern populations [38] . This status may be explained by the differences in etiologic factors such as viral infections and exposure to environmental factors as well as differences in the genetic susceptibility. Furthermore, substantial ethnic differences existed with respect to molecular features of malignant tumors [31, [48] [49] [50] . [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] No significant association between MGMT promoter methylation status and the two immunophenotypic differentiation profiles was observed in this study. Al-Kuraya et al. [31] investigated the interrelationship between MGMT methylation status and immunohistochemical coexpression of CD10/bcl-6, and they did not show a significant association. Furthermore, Al-Kuraya et al. determined that their frequency of GCB profile DLBCL (13%) was somewhat lower than described in previous studies. They also found a much higher rate of MGMT methylation in their patients (75.9%) as compared with previous studies [1, 3, 30, 31, 46, 47] . In our study, no significant association was found between MGMT promoter methylation status and the expression levels of apoptosis-related proteins, the AI and the PI. There is no similar previous study searching the relation of MGMT promoter methylation and expression levels of apoptosis-related proteins, the AI and the PI. Further studies could be done to elucidate the role of MGMT promote methylation in DLBCLs.
In summary, these results suggest that bcl-6 protein expression may be responsible for the high PI in the GCB profile of DLBCLs. Additionally, we found that expression status of apoptosis-related bcl-2 family proteins (bcl-2, bcl-xl, bax, bak, bid) was not significantly associated with the immunophenotypic differentiation profiles. We also determined that there was no significant association between MGMT promoter methylation status and the immunophenotypic differentiation profiles of DLBCLs. 
